AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17186712 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium
Number of subjects: 0
Study 17186712 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study 17186712 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin
Number of subjects: 0
Study 17186712 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin (immediate-release)
Number of subjects: 0
Study 17186712 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (immediate-release)
Number of subjects: 0
Study 17186712 — intervention group
Group type: COMPARATOR
Intervention: Extended-release formulations of Tolterodine or Oxybutynin
Number of subjects: 0
Study 12762623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (A)
Number of subjects: 52
Study 12762623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and strength training (AS)
Number of subjects: 52
Study 11164433 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time physical activity
Number of subjects: 1778
Study 11164433 — intervention group
Group type: COMPARATOR
Intervention: TV watching
Number of subjects: 1778
Study 11164433 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time physical activity and TV watching
Number of subjects: 1778
Study 9264626 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief medical counselling backed up by didactic material
Number of subjects: 152
Study 9264626 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 152
Study 8383657 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 113
Study 8383657 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 113
Study 3082257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS) pressurized aerosol, 1 mg per puff, 2 puffs, four times daily for 4 weeks
Number of subjects: 14
Study 3082257 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 puffs, four times daily for 4 weeks
Number of subjects: 14
Study 3082257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS) pressurized aerosol
Number of subjects: 14
Study 3082257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31809457 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Failure (MF) training protocol
Number of subjects: 10
Study 31809457 — intervention group
Group type: COMPARATOR
Intervention: No Muscle Failure (NMF) training protocol
Number of subjects: 10
Study 31809457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MF and NMF protocols
Number of subjects: 10
Study 31809457 — intervention group
Group type: EXPERIMENTAL
Intervention: NMF training
Number of subjects: 10
Study 31520633 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiation Therapy (RT)
Number of subjects: 1215
Study 31520633 — intervention group
Group type: COMPARATOR
Intervention: No Adjuvant Radiation Therapy (RT)
Number of subjects: 1215
Study 27449925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-enriched Gouda-type cheese (60 g providing 5.7 μg of vitamin D3 daily)
Number of subjects: 79
Study 27449925 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched Gouda-type cheese (control group)
Number of subjects: 79
Study 27449925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-enriched Gouda-type cheese
Number of subjects: 79
Study 26860022 — intervention group
Group type: EXPERIMENTAL
Intervention: I-GEL
Number of subjects: 64
Study 26860022 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 64
Study 23167912 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐MIST with rhPDGF‐BB gel
Number of subjects: 24
Study 23167912 — intervention group
Group type: COMPARATOR
Intervention: M‐MIST alone
Number of subjects: 24
Study 21296957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (5.0 g daily, containing 2.0 g of EPA and 1.0 g of DHA)
Number of subjects: 116
Study 21296957 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (5.0 g of corn/soy mixture)
Number of subjects: 116
Study 21296957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 116
Study 19467834 — intervention group
Group type: COMPARATOR
Intervention: Isothermic cardioplegia alone
Number of subjects: 53
Study 19467834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegia enriched with NAC (50mg/kg body weight)
Number of subjects: 53
Study 17088135 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with mild asthma
Number of subjects: 196
Study 17088135 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with moderate-severe asthma
Number of subjects: 196
Study 17088135 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with asthma with GSTP1 val/val genotype
Number of subjects: 196
Study 17088135 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 val/val genotype
Number of subjects: 196
Study 17088135 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 196
Study 15248793 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal speech intervention (12 children)
Number of subjects: 24
Study 15248793 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated speech intervention (12 children)
Number of subjects: 24
Study 15248793 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 children)
Number of subjects: 24
Study 11374698 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/O2 inhalation (50% N2O/O2)
Number of subjects: 100
Study 11374698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (breathing oxygen)
Number of subjects: 100
Study 9258161 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block after surgery
Number of subjects: 98
Study 9258161 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block before surgery
Number of subjects: 98
Study 9258161 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block before and after surgery
Number of subjects: 98
Study 9258161 — intervention group
Group type: COMPARATOR
Intervention: Control group (after surgery only)
Number of subjects: 98
Study 8299548 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (specific type not mentioned)
Number of subjects: 0
Study 8299548 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitor (MAOI) phenelzine
Number of subjects: 0
Study 8299548 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic therapy
Number of subjects: 0
Study 8299548 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine and lithium
Number of subjects: 0
Study 8299548 — intervention group
Group type: COMPARATOR
Intervention: Anti-depressants
Number of subjects: 0
Study 2936958 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1
Study 2936958 — intervention group
Group type: COMPARATOR
Intervention: Placebo or alternative treatment
Number of subjects: 1
Study 31036033 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D adjustable cervico thoracic posture corrective orthotic (CTPCO)
Number of subjects: 24
Study 31036033 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (moist hot pack, soft tissue mobilization, manual therapy, therapeutic exercise)
Number of subjects: 24
Study 27760505 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity function training (UE group) for three months
Number of subjects: 15
Study 27760505 — intervention group
Group type: COMPARATOR
Intervention: Lower extremity function training (LE group) for three months
Number of subjects: 15
Study 25926725 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g leucine/day plus resistance training (leucine group [LG], n=15)
Number of subjects: 30
Study 25926725 — intervention group
Group type: COMPARATOR
Intervention: Resistance training only (control group [CG], n=15)
Number of subjects: 30
Study 23449843 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated increase in relative right frontal cortical activity
Number of subjects: 0
Study 23449843 — intervention group
Group type: COMPARATOR
Intervention: Manipulated increase in relative left frontal cortical activity
Number of subjects: 0
Study 23449843 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 21454006 — intervention group
Group type: EXPERIMENTAL
Intervention: AED with audiovisual feedback enabled
Number of subjects: 68
Study 21454006 — intervention group
Group type: COMPARATOR
Intervention: Control group (AED with audiovisual feedback disabled)
Number of subjects: 68
Study 19631788 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless IUD (GyneFix)
Number of subjects: 4063
Study 19631788 — intervention group
Group type: COMPARATOR
Intervention: TCu380A IUD
Number of subjects: 4063
Study 16368340 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 141
Study 16368340 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy
Number of subjects: 141
Study 12600870 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (20% of total amino acids as glutamine)
Number of subjects: 141
Study 12600870 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous amino acid solution (without glutamine)
Number of subjects: 141
Study 12600870 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 141
Study 11022928 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support
Number of subjects: 590
Study 11022928 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 590
Study 8852863 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 lux of bright light
Number of subjects: 18
Study 8852863 — intervention group
Group type: COMPARATOR
Intervention: < 500 lux of dim light (placebo)
Number of subjects: 18
Study 8852863 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of light exposure
Number of subjects: 18
Study 1537959 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (35.21 mg/day)
Number of subjects: 48
Study 1537959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6726596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplements from the 16th week of amenorrhea until 6 weeks post partum
Number of subjects: 44
Study 6726596 — intervention group
Group type: COMPARATOR
Intervention: Control group without iron supplementation
Number of subjects: 44
Study 29659116 — intervention group
Group type: EXPERIMENTAL
Intervention: DC0120 (5% minoxidil formulation), applied twice per day for 16 weeks
Number of subjects: 220
Study 29659116 — intervention group
Group type: COMPARATOR
Intervention: Comparator (ALOSTIL® minoxidil product), applied twice per day for 16 weeks
Number of subjects: 220
Study 29659116 — intervention group
Group type: COMPARATOR
Intervention: DC0120 and Comparator (both minoxidil treatments)
Number of subjects: 220
Study 29659116 — intervention group
Group type: COMPARATOR
Intervention: DC0120 vs Comparator
Number of subjects: 220
Study 28935431 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral portal for suture anchor placement
Number of subjects: 10
Study 28935431 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral portal for suture anchor placement
Number of subjects: 10
Study 28935431 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical strength assessment
Number of subjects: 10
Study 27572136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methadone (0.1-0.125 mg/kg) in addition to standard care
Number of subjects: 47
Study 27572136 — intervention group
Group type: COMPARATOR
Intervention: Standard care (opioid patient-controlled analgesia)
Number of subjects: 47
Study 24699248 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK263 (300 mg BID)
Number of subjects: 141
Study 24699248 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK263 (co-dosed with metformin)
Number of subjects: 141
Study 24699248 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 141
Study 24699248 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (co-dosed with metformin)
Number of subjects: 141
Study 24699248 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK263
Number of subjects: 141
Study 21337116 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 1 month
Number of subjects: 24
Study 21337116 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 24
Study 20036477 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem
Number of subjects: 0
Study 18614738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 capsules of 1g providing 2.7g n-3 PUFAs per day)
Number of subjects: 533
Study 18614738 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (4 capsules of 1g per day)
Number of subjects: 533
Study 18614738 — intervention group
Group type: COMPARATOR
Intervention: No oil capsules
Number of subjects: 533
Study 16139934 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge (dental) needle
Number of subjects: 86
Study 16139934 — intervention group
Group type: COMPARATOR
Intervention: 23-gauge needle
Number of subjects: 86
Study 11854696 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units of botulinum toxin (retreatment with 30 units if fissure persisted)
Number of subjects: 150
Study 11854696 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 units of botulinum toxin (retreatment with 50 units if fissure persisted)
Number of subjects: 150
Study 10235530 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3 treatment at 1.0 mg/kg/day
Number of subjects: 29
Study 10235530 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3 treatment at 2.0 mg/kg/day
Number of subjects: 29
Study 10235530 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3 treatment at 4.0 mg/kg/day
Number of subjects: 29
Study 10235530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IGF-1/IGFBP-3 treatment)
Number of subjects: 29
Study 8904257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.056 mg/kg
Number of subjects: 40
Study 8904257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.14 mg/kg
Number of subjects: 40
Study 8904257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.28 mg/kg
Number of subjects: 40
Study 8904257 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.28 mg/kg
Number of subjects: 40
Study 1824542 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein formula (1.4 gm protein/100 ml)
Number of subjects: 0
Study 1824542 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented human milk (1.4 gm protein/100 ml)
Number of subjects: 0
Study 1824542 — intervention group
Group type: COMPARATOR
Intervention: Control group (fresh human milk)
Number of subjects: 0
Study 6405766 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride 0.4 mg with isobaric 0.5% bupivacaine
Number of subjects: 2
Study 6405766 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.2 mg (older patients only)
Number of subjects: 2
Study 6405766 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 30665731 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD (n = 217)
Number of subjects: 442
Study 30665731 — intervention group
Group type: COMPARATOR
Intervention: In-person, group class (n = 225)
Number of subjects: 442
Study 29106676 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolock/Hep
Number of subjects: 164
Study 29106676 — intervention group
Group type: COMPARATOR
Intervention: Taurolock/U
Number of subjects: 164
Study 26297132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested 0.3 g of raw salmon
Number of subjects: 10
Study 26297132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested 30 g of raw salmon
Number of subjects: 10
Study 23972906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led care coordination with experienced nurse practitioners and a best practice resource guide
Number of subjects: 0
Study 23972906 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 22595107 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 55
Study 22595107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 55
Study 19467149 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity counseling (PAC)
Number of subjects: 398
Study 19467149 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 398
Study 17460331 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 20
Study 17460331 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 20
Study 17460331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15509514 — intervention group
Group type: EXPERIMENTAL
Intervention: AdvHSV‐tk gene therapy (3 x 10(10) pfu) followed by intravenous ganciclovir (GCV), 5 mg/kg twice daily for 14 days
Number of subjects: 36
Study 15509514 — intervention group
Group type: COMPARATOR
Intervention: Standard care (radical excision followed by radiotherapy)
Number of subjects: 36
Study 10702179 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula
Number of subjects: 926
Study 10702179 — intervention group
Group type: COMPARATOR
Intervention: Banked donor breast milk
Number of subjects: 926
Study 10702179 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula
Number of subjects: 926
Study 9322826 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine-capsules (10 mg)
Number of subjects: 46
Study 9322826 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril (25 mg)
Number of subjects: 46
Study 9322826 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine-retard (20 mg)
Number of subjects: 46
Study 8447800 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin treatment
Number of subjects: 23
Study 8447800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3462391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 30
Study 3462391 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 3462391 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Lidocaine and Saline
Number of subjects: 30
Study 2967783 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene
Number of subjects: 20
Study 2967783 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel
Number of subjects: 20
Study 2967783 — intervention group
Group type: COMPARATOR
Intervention: Both antiovulants
Number of subjects: 20
Study 31770598 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (APDT)
Number of subjects: 0
Study 31770598 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 0
Study 31229609 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom (home pre‐taped lectures followed by in‐class group exercise)
Number of subjects: 40
Study 31229609 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom (home reading assignment followed by in‐class lecture)
Number of subjects: 40
Study 29049902 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment with Prolonged Exposure (COPE)
Number of subjects: 110
Study 29049902 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT)
Number of subjects: 110
Study 29049902 — intervention group
Group type: COMPARATOR
Intervention: Active Monitoring Control Group (AMCG)
Number of subjects: 110
Study 26769459 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg daily for 12 weeks
Number of subjects: 30
Study 26769459 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 30
Study 23442834 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2a (40 kDa) plus ribavirin for 72 weeks
Number of subjects: 942
Study 23442834 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alpha‐2a (40 kDa) plus ribavirin for 48 weeks
Number of subjects: 942
Study 23442834 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 weeks of treatment
Number of subjects: 942
Study 23442834 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks of treatment
Number of subjects: 942
Study 23442834 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping treatment at week 12 for non-cEVR patients
Number of subjects: 942
Study 23442834 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping treatment at week 12 for cEVR patients
Number of subjects: 942
Study 22168328 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal weight-reduction program
Number of subjects: 54
Study 18647396 — intervention group
Group type: COMPARATOR
Intervention: Remote therapy (telephone, internet, videoconference)
Number of subjects: 894
Study 16834839 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 80 000 U every 2 weeks (Q2W)
Number of subjects: 310
Study 16834839 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 40 000 U weekly (QW)
Number of subjects: 310
Study 15017641 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 15017641 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus fentanyl
Number of subjects: 100
Study 10693734 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of orlistat TID
Number of subjects: 796
Study 10693734 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of orlistat TID
Number of subjects: 796
Study 10693734 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID
Number of subjects: 796
Study 9490144 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide 3.75 mg LP
Number of subjects: 68
Study 9490144 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin 3.75 mg LP
Number of subjects: 68
Study 8353106 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting skills training programme
Number of subjects: 0
Study 8353106 — intervention group
Group type: COMPARATOR
Intervention: Control group (students not trained in consulting skills)
Number of subjects: 0
Study 3754233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bd + Pirenzepine 50 mg bd
Number of subjects: 8